β-blockers: The new standard of therapy for mild heart failure

Archives of Internal Medicine

Volumn 160, Issue 9, 2000, Pages 1237-1247

  Abraham, William T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0034621495     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.9.1237     Document Type: Review

References (81)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
3. Abraham WT, Hensen J, Schrier RW. Elevated plasma noradrenaline concentrations in patients with low-output cardiac failure: dependence on increased noradrenaline secretion rates. Clin Sci. 1990;79:429-435.
4. Feldman AM, Bristow MR. Adrenergic neuroeffector mechanisms in the failing human heart. In: Braunwald E, ed. Clinical Update, Heart Disease. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1990: 206-216.
5. Bristow MR, Hershberger RE, Port JD, et al. β-Adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990; 82(suppl 1):12-25.
6. Francis GS, Cohn JN, Johnson G, et al, for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 1993; 87(suppl 6):VI40-VI48.
7. Cohn JN. Plasma norepinephrine and mortality. Clin Cardiol. 1995;18(suppl 1):l9-l12.
8. Remme WJ. Congestive heart failure: pathophysiology and medical treatment. J Cardiovasc Pharmacol. 1986;8(suppl 1):S36-S52.
9. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
10. Katz AM. Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol. 1995;18(9, suppl 4):36-44.
11. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 1997;80:15L-25L.
12. Horban A, Kolbeck-Ruhmkorff C, Zimmer HG. Correlation between function and proto-oncogene expression in isolated working rat hearts under various overload conditions. J Mol Cell Cardiol. 1997; 29:2903-2914.
13. Zimmer HG. Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J Mol Med. 1997;75:849-859.
14. Jaffe R, Flugelman MY, Halon DA, Lewis BS. Ventricular remodeling: from bedside to molecule. Adv Exp Med Biol. 1997;430:257-266.
15. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol. 1991;68:1D-6D.
16. Mulieri LA, Hasenfuss G, Leavitt B, et al. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85:1743-1750.
17. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(4 suppl A):61A-71A.
18. Packer M, Gottlieb SS, Kessler PD. Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure: basis of a new physiologic approach to control of arrhythmia. Am J Med. 1986;80:23-29.
19. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol. 1992;19:1622-1633.
20. Oakley C. Genesis of arrhythmias in the failing heart and therapeutic implications. Am J Cardiol. 1991; 67:26C-28C.
21. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a sub-study of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
22. Abraham WT. Systolic vs diastolic heart failure: therapeutic considerations. Cardiovasc Rev Rep. 1998;19:59-68.
23. Bourassa MG, Gurne O, Bangdiwala SI, et al, for the Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14A-19A.
24. Kannel WB, Ho K, Thom T. Changing epidemiologic features of cardiac failure. Br Heart J. 1994; 72(suppl):3-9.
25. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995;26:1376-1398.
26. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic failure: an epidemiologic perspective. J Am Coll Cardiol. 1995; 26:1565-1574.
27. Abraham WT, Schrier RW. Use of furosemide in the treatment of congestive heart failure. In: Aspects of Diuretic Therapy With Furosemide: An Update. Kent, England: Wells Medical Ltd; 1993:23-33.
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
29. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-1456.
30. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
31. Cohn JN, Fowler MB, Bristow MR, et al, for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173-179.
32. Doughty RN, Whalley GA, Gamble G, et al, for the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997;29:1060-1066.
33. Waagstein F, Bristow MR, Swedberg K, et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446.
34. Bristow MR, O'Connell JB, Gilbert EM, et al, for the Bucindolol Investigators. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
35. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
36. Colucci WS, Packer M, Bristow MR, et al, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996; 94:2800-2806.
37. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise (PRECISE) Trial. Circulation. 1996;94: 2793-2799.
38. Packer M, Cohn J for the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol. 1999;83 (Suppl 2A):1A-38A.
39. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J-P, Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191.
40. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomized controlled trials. Eur Heart J, 1997; 18:560-565.
41. Heidenreich PA, Lee TT, Massie B. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 1997;30:27-34.
42. Packer M. β-Adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41 (suppl 1):39-52.
43. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
44. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther. 1992;263:92-98.
45. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens. 1993;11(suppl): S41-S48.
46. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA. 1993;90:6189-6193.
47. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993;21:221-227.
48. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678-1687.
49. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92: 1499-1506.
50. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
51. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol. 1988;62:25A-30A.
52. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375-380.
53. The International Steering Committee tor the MERIT-HF Study Group. Rationale, design, and organization of the Metoprolol CR/XL Randomization Intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol. 1997;80(suppl 9B):54J-58J.
54. The BEST Steering Committee. Design of the Beta-blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.
55. Bristow MR, Colucci WS, Fowler MB, et al. Effect of carvedilol on survival and hospitalization in patients with ischemic or nonischemic cardiomyopathy [abstract]. Circulation. 1996;94:1338.
56. Packer M. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol. 1997;80(suppl 11A):46L-54L.
57. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
58. Cohn JN, Johnson G, Zeische S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration cooperative study. N Engl J Med. 1986; 314:1547-1552.
59. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327: 685-691.
60. Gheorhiade M, Benatar D, Konstam MA, Stoukides CA, Bonow RO. Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. Am J Cardiol. 1997;80(suppl 8B):14H-27H.
61. Packer M, O'Conner CM, Ghali JK, et al, for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 1996;335:1107-1114.
62. Packer M, Carver JR, Rodeheffer RJ, et al, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468-1475.
63. Pfeffer MA, Stevenson LW. β-Adrenergic blockers and survival in heart failure [editorial]. N Engl J Med. 1996;334:1396-1397.
64. Moye LA, Abernethy D. Carvedilol in patients with chronic heart failure [letter]. N Engl J Med. 1996; 335:1318.
65. Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE Study [abstract]. Circulation. 1993;88(suppl 1):I301.
66. Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure [letter]. N Engl J Med. 1996;335:1319.
67. Packer M. β-Blockade in heart failure: basic concepts and clinical results. Am J Hypertens. 1998; 11:23S-37S.
68. Doughty RN, MacMahon S, Sharpe N. Beta-blockers in heart failure: promising or proved? J Am Coll Cardiol. 1994; 23:814-821.
69. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and anti-adrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
70. Abraham WT, Tsvetkova T, Lowes BD, et al. Carvedilol improves renal hemodynamics in patients with chronic heart failure [abstract]. J Card Fail. 1998; 4(suppl 1):3.
71. Krukmeyer JJ. Use of beta-adrenergic blocking agents in congestive heart failure. Clin Pharmacol. 1990;9:853-863.
72. Hall S, Cigarroa C, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
73. Sackner-Bernstein JD. Use of carvedilol in chronic heart failure: challenges in therapeutic management. Prog Cardiovasc Dis. 1998;41 (suppl 1):53-58.
74. Frishman WH. Drug therapy: carvedilol. N Engl J Med. 1998;339:1759-1765.
75. Sackner-Bernstein JD, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of β-blocker therapy for chronic heart failure preclude long-term treatment? [abstract]. Circulation. 1995;92(suppl 1):I395.
76. Kropff S, Simon P, Hoebel W, Meister W. Titration of carvedilol in patients with stable congestive heart failure: experience from an observational cohort study [abstract]. Presented at: European Society of Cardiology; August 24, 1998; Vienna, Austria.
77. Fowler MB, Gilbert EM, Conn JN, et al, for the Carvedilol Heart Failure Study Group. Effects of carvedilol on cardiovascular hospitalizations in patients with chronic heart failure [abstract]. J Am Coll Cardiol. 1996;(suppl A):169A.
78. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83:890-896.
79. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73:503-510.
80. Hjalmarson A, Kneider M, Waagstein F. The role of β-blockers in left ventricular dysfunction and heart failure. Drugs. 1997;54:501-510.
81. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): sub-group findings from randomized trials in post infarction patients. Eur Heart J. 1988;9:8-16.